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Supplementary Figure 1. Regional and tissue expression plots. 
(a) female-specific and (b) male-specific for established IRS1 locus with sex-dimorphic 
effects on FI, (c) female-specific and (d) male-specific on FG for novel RGS17 locus; e) 
RGS17 tissue expression relative to three housekeeping genes (PPIA, B2M and HPRT). For 
beta cell (n=3) and islets (n=3) data, lines are means. Quantitative RT-PCR was carried out 
using cDNAs from three human donors (beta-cells and islets). The other tissues were 
commercial cDNAs (one point observation); Regional plots for (f) novel MANBA/UBE2D3 
locus with homogeneous effects between men and women (no conditioning), (g) 
association analysis of MANBA/UBE2D3 signal conditioned on ulcerative colitis 
(rs3774959) established variant and (h) association analysis of MANBA/UBE2D3 signal 






Supplementary Figure 2. Regional plots for novel loci with sex-combined effects on FG.  








Supplementary Figure 3. GARFIELD enrichment analysis. Enrichment results for the sex-
specific FG meta-analysis summary statistics: (a) peaks, (b) histone modifications and (c) 










Supplementary Figure 4. Tissue expression of genes within the novel ZNF12 locus.  
(a) KDELR2 and (b) DAGLB. Expression is relative to three housekeeping genes (PPIA, B2M 
and HPRT). For beta cell (n=3) and islets (n=3) data, lines are means. Quantitative RT-PCR 
was carried out using cDNAs from three human donors (beta-cells and islets). The other 








Supplementary Figure 5. Power of tests for detecting sex heterogeneity through 
simulations.  
Power of sex-combined, sex-dimorphic and female-specific analyses, as well as Cochran’s 
Q-test to detect associations for evidence of sex heterogeneity under three scenarios of 
sex-effects: no sex heterogeneity at (a) CAF=0.2, and (b) CAF=0.5, effects on both sexes 
with the presence of heterogeneity between them at (c) CAF=0.2 and (d) CAF=0.5, an 
effect specific to one sex only, e.g. women at (e) CAF=0.2 and (f) CAF=0.5. Power of the 
current sample size to detect sex heterogeneity at established FG (n=36) and FI (n=19) loci 
using the approach that ignores Psex-dimorphic and considers only Pheterogeneity<0.05 or 
Pheterogeneity adjusted for multiple testing (Pheterogeneity<0.05/36 or Pheterogeneity<0.05/19) 
under two scenarios of sex-effects: an effect specific to one sex only, e.g. women and 
effects on both sexes with the presence of heterogeneity between them considering four 
CAFs: (g) CAF=0.05, (h) CAF=0.1, (i) CAF=0.2, (j) CAF=0.5. The power at P<5x10-8 is given 
for all three tests: sex-combined, sex-dimorphic and female-specific. Colour coding for 
panels (g-j) is given on panel (g). The power for the heterogeneity test implemented in 
GWAMA (Cochran’s Q-test) is also given.  Simulations were based on 70,000 men and 
70,000 women. For each parameter setting, 10,000 replicates of data were generated. 
CAF is the causal variant allele frequency and beta is the effect size in SD units in 
women. Within each scenario, we considered two CAFs (0.2 and 0.5) and a range of betas 
(from 0 to 0.1) representing the effect size in SD units in women. For the no sex-
heterogeneity setting, the beta in men is the same as in women; for the sex-dimorphic 
setting, the beta in men is fixed at 0.05 SD units; for the female-specific setting, the beta 
in men is fixed at zero. 
 
 
 
 
 
